ArticleCurrent medicinal chemistry2026
Identification of Small Extracellular Vesicle (sEV)-Related Genes and the Establishment of Diagnostic Models for Esophageal Cancer.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionEsophageal cancer (EC) remains a global health challenge with high incidence and mortality. While sEV-related genes (ERGs) are emerging as key players in the tumor microenvironment, their diagnostic and pathogenic roles in EC are still poorly characterized.
methodsThis study employed integrated bioinformatics approaches to identify ERGbased diagnostic biomarkers and molecular mechanisms in EC. Four GEO datasets were analyzed to identify differentially expressed genes (DEGs), which were cross-referenced with ERGs from GeneCards and the literature. Functional enrichment analyses (GO/KEGG), Cytoscape network analysis, and machine learning algorithms (LASSO, SVM, random forest) were used to prioritize diagnostic markers. Immune infiltration patterns were assessed via ssGSEA, and key genes were validated by qRT‒PCR in EC and normal cells.
resultsWe identified 456 DEGs, including 34 sEV-related ERDEGs enriched in bacterial defense response, secretory granule lumen, calcium-dependent protein binding, and pathways such as proteoglycans in cancer and IL-17 signaling. GSEA highlighted cell cycle, ECM-receptor interaction, and DNA replication as central mechanisms. DISCUSSION: Machine learning pinpointed EpCAM and RUVBL1 as robust diagnostic biomarkers, validated by their elevated expression in EC cell lines. Immune infiltration analysis revealed correlations between these genes and 20 immune cell types, underscoring their relevance to the tumor microenvironment.
conclusionEpCAM and RUVBL1 are promising diagnostic biomarkers for EC, linking sEV-mediated pathways to disease progression. These findings provide insights into EC pathogenesis and highlight potential therapeutic targets.
Indexed as
Identifiers
41664333What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.